GSK News

Jittery sentiment has ruled stock markets for the better part of the last week, as investors remain cautious over the potential impact of a blown-out trade war. However, some stocks have shown resilience and look likely to stay on the upside amidst the chaos. Nvidia, GlaxoSmithKline (GSK) and Taiwan Semiconductor Manufacturing Company (TSCM) stocks are among them. Nvidia Nvidia stock price looks to have weathered the storm caused by DeepSeek in the last week of January. Much as it is yet to bounce back to its post-split record highs of $140 the FUD sentiment surrounding the stock seems to have dissipated. Many analysts opine that while the DeepSeek phenomenon is impactful, it is unlikely to eat into a substantial section of Nvidia's market. Leading tech companies are likely to keep focusing on AI as their growth frontier for the foreseeable future. The strongest tailwind for Nvidia stock price in the coming weeks is likely to come from its earnings reports. This will be the first time the company will release revenue figures for its Blackwell chips, and there is strong evidence to expect forecast-beating earnings. The Nvidia (NASDAQ: NVDA) CEO Jensen Huang previously described the demand for the chips as "insane." Nvidia Stock Price Prediction Pivot: Nvidia stock price pivots at 119.35. Action above that level will favour the buyers to be in control. Otherwise the downward momentum will prevail. Resistance: The first resistance at $122.10. Second at $123.90 Support: S1 at $117.60. Breaking blow that level will invalidate the upside narrative. The second support is likely to be at $115.45. GlaxoSmithKline The momentum on GlaxoSmithKline (LSE: GSK) stock price is attributed to strong earnings in the quarter ending December 2024. On Tuesday, the company reported sales of £8.12 billion against median forecasts of £7.75 billion. Core EPS stood at GBX 23.2, beating forecast of GBX 19. Also, the company expects revenue growth of between 3%-5% in 2025 and targets to generate revenue of £51 billion in 2031, driven by a focus on specialty medicine. Investing more in specialty medicine is seen as a critical growth path as vaccines face challenging times amid declining public support. US Health Secretary nominee Robert F. Kennedy Jr, a known skeptic of vaccines, is likely to be approved by the Senate. That could usher a reign of reduced uptake of vaccines, adding credence to the need to diversify revenue sources. The momentum on GSK stock price is likely to be sentiment-driven in the near-term, but strong fundamentals also favour growth. GSK Stock Price Prediction Pivot: The stock pivots at GBX 1,459. Resistance: First resistance at GBX 1,474. The second one at GBX 1,489. The first support is likely to come at GBX 1,449, below which the upside narrative will be invalid. Second support at GBX 1,436. Taiwan Semiconductor Manufacturing Company (TSM) Like Nvidia, TSM stock price was under pressure in the last week of January due to the DeepSeek riot. However, as the dust settles, the world's leading manufacturer of semiconductor chips seems unlikely to veer of its growth trajectory. If anything, some analysts think that DeepSeek is a blessing to TSM. According to the latest report by JP Morgan, if DeepSeek's R1 Large Language Model can be implemented on low compute power gadgets like notebooks and smartphones, it could lead to a substantial spike in demand for AI chips. That translates to more demand for TSM (NYSE: TSM) products and ultimately favours gains by the TSM stock price. This news is likely to propel the stock up in the coming days. TSM Stock Price Prediction Pivot: Pivot point is at $203.08 Resistance: The first resistance is likely to be at $206.55, above which the next target could come at $210.00 Support: Primary support at $200.90. Breaking below that mark will invalidate the upside narrative. Second support could come at $198.90.

GSK

Top Stock Price Prediction: Strong Tailwinds On Nvidia, GSK, TSCM Stocks

GSK Share Price Gets Rejected From 200 MA – What’s Next?

GlaxoSmithKline Share Price: Uptrend Intact Despite Correction

GSK Share Price: More Gains Likely After the Unilever Offer

GSK Share Price: Can Dormitzer’s Appointment Stop the Near-Term Correction?

GSK Share Price: HIV Drug Update in Focus

GSK Share Price Unmoved Despite $1billion Deal With Arrowhead Pharma

GSK Share Price Hits New 2021 Highs Despite Denial of Aurinia Takeover Bid

GSK Share Price Undervalued, Says Research Firm Berenberg

GSK Share Price Surges On Reported Interest from Private Equity Firms

GSK Share Price Forms H&S as Activist Pressure Builds

GSK Share Price Aims for 1400p As FDA Grants Priority Review for Cabotegravir

Subscribe to our newsletter